{
  "epistasis_pairs": {
    "CYP2D6_loss+CYP3A4_rs776746_TT": {
      "weight": 0.45,
      "evidence": [
        "Combined CYP2D6 and CYP3A4 impairment severely reduces codeine activation",
        "PharmGKB Level 1A: Poor metabolizers at high risk for treatment failure"
      ],
      "drugs": [
        "codeine"
      ]
    },
    "CYP2D6_loss+CYP3A4_reduced": {
      "weight": 0.35,
      "evidence": [
        "Dual pathway impairment increases risk of inadequate analgesia",
        "Consider alternative opioid or dose adjustment"
      ],
      "drugs": [
        "codeine"
      ]
    },
    "CYP2C19_loss+CYP3A4_reduced": {
      "weight": 0.4,
      "evidence": [
        "Clopidogrel activation significantly impaired with dual enzyme deficiency",
        "FDA boxed warning for poor CYP2C19 metabolizers"
      ],
      "drugs": [
        "clopidogrel"
      ]
    },
    "CYP2C9_loss+VKORC1_low_dose": {
      "weight": 0.5,
      "evidence": [
        "Warfarin sensitivity markedly increased; high bleeding risk",
        "Requires substantial dose reduction per CPIC guidelines"
      ],
      "drugs": [
        "warfarin"
      ]
    },
    "SLCO1B1_reduced+CYP3A4_reduced": {
      "weight": 0.38,
      "evidence": [
        "Increased simvastatin exposure and myopathy risk",
        "Consider lower dose or alternative statin"
      ],
      "drugs": [
        "simvastatin"
      ]
    },
    "TPMT_loss+NUDT15_loss": {
      "weight": 0.6,
      "evidence": [
        "Severe thiopurine toxicity risk with dual enzyme deficiency",
        "Consider alternative immunosuppressant"
      ],
      "drugs": [
        "azathioprine",
        "mercaptopurine"
      ]
    },
    "DPYD_loss+TYMS_reduced": {
      "weight": 0.65,
      "evidence": [
        "Severe fluoropyrimidine toxicity risk",
        "Consider alternative chemotherapy"
      ],
      "drugs": [
        "fluorouracil",
        "capecitabine"
      ]
    },
    "UGT1A1_reduced+CYP3A4_reduced": {
      "weight": 0.5,
      "evidence": [
        "Increased irinotecan toxicity risk",
        "Consider dose reduction or alternative"
      ],
      "drugs": [
        "irinotecan"
      ]
    },
    "CYP2D6_loss+CYP1A2_reduced": {
      "weight": 0.35,
      "evidence": [
        "Dual pathway impairment for clozapine metabolism",
        "May require dose adjustment"
      ],
      "drugs": [
        "clozapine"
      ]
    },
    "CYP3A4_reduced+CYP3A5_loss": {
      "weight": 0.3,
      "evidence": [
        "Reduced tacrolimus and cyclosporine metabolism",
        "May require dose adjustment"
      ],
      "drugs": [
        "tacrolimus",
        "cyclosporine"
      ]
    }
  },
  "single_tags": {
    "CYP2D6_loss": {
      "weight": 0.3,
      "evidence": [
        "Complete loss of CYP2D6 function affects ~7% of Caucasians",
        "Critical for codeine, tramadol, and many antidepressants"
      ]
    },
    "CYP2D6_reduced": {
      "weight": 0.15,
      "evidence": [
        "Intermediate metabolizer status",
        "May require dose adjustment for CYP2D6 substrates"
      ]
    },
    "CYP2C19_loss": {
      "weight": 0.28,
      "evidence": [
        "Poor metabolizer phenotype for clopidogrel and PPIs",
        "FDA boxed warning for clopidogrel in poor metabolizers"
      ]
    },
    "CYP2C19_reduced": {
      "weight": 0.14,
      "evidence": [
        "Intermediate metabolizer status",
        "Reduced activation of prodrugs"
      ]
    },
    "CYP2C19_ultrarapid": {
      "weight": 0.1,
      "evidence": [
        "Increased metabolism may reduce efficacy of some drugs",
        "May require higher doses of PPIs"
      ]
    },
    "CYP3A4_rs776746_TT": {
      "weight": 0.18,
      "evidence": [
        "Reduced CYP3A4 expression",
        "Affects many commonly prescribed medications"
      ]
    },
    "CYP3A4_reduced": {
      "weight": 0.12,
      "evidence": [
        "Intermediate CYP3A4 function",
        "Monitor for drug accumulation"
      ]
    },
    "CYP2C9_loss": {
      "weight": 0.32,
      "evidence": [
        "High warfarin sensitivity",
        "Increased bleeding risk with standard dosing"
      ]
    },
    "CYP2C9_reduced": {
      "weight": 0.18,
      "evidence": [
        "Intermediate metabolizer for warfarin and NSAIDs",
        "Dose reduction often required"
      ]
    },
    "VKORC1_low_dose": {
      "weight": 0.22,
      "evidence": [
        "Increased warfarin sensitivity",
        "Requires lower maintenance dose"
      ]
    },
    "SLCO1B1_reduced": {
      "weight": 0.25,
      "evidence": [
        "Increased statin myopathy risk",
        "CPIC recommendation: consider alternative or lower dose"
      ]
    },
    "ABCB1_reduced_function": {
      "weight": 0.1,
      "evidence": [
        "Altered drug transport",
        "May affect bioavailability of many drugs"
      ]
    },
    "TPMT_loss": {
      "weight": 0.45,
      "evidence": [
        "Severe thiopurine toxicity risk",
        "FDA boxed warning for azathioprine and mercaptopurine"
      ],
      "drugs": [
        "azathioprine",
        "mercaptopurine"
      ]
    },
    "TPMT_reduced": {
      "weight": 0.25,
      "evidence": [
        "Intermediate thiopurine toxicity risk",
        "Dose reduction required"
      ],
      "drugs": [
        "azathioprine",
        "mercaptopurine"
      ]
    },
    "DPYD_loss": {
      "weight": 0.5,
      "evidence": [
        "Severe fluoropyrimidine toxicity risk",
        "FDA recommendation for DPYD testing"
      ],
      "drugs": [
        "fluorouracil",
        "capecitabine"
      ]
    },
    "DPYD_reduced": {
      "weight": 0.3,
      "evidence": [
        "Intermediate fluoropyrimidine toxicity risk",
        "Dose reduction required"
      ],
      "drugs": [
        "fluorouracil",
        "capecitabine"
      ]
    },
    "UGT1A1_reduced": {
      "weight": 0.35,
      "evidence": [
        "Increased irinotecan toxicity risk",
        "FDA recommendation for UGT1A1 testing"
      ],
      "drugs": [
        "irinotecan"
      ]
    },
    "HLA-B_risk": {
      "weight": 0.4,
      "evidence": [
        "HLA-B*5701 allele associated with severe hypersensitivity",
        "FDA boxed warning for abacavir, carbamazepine, allopurinol"
      ],
      "drugs": [
        "abacavir",
        "carbamazepine",
        "allopurinol"
      ]
    },
    "CYP1A2_reduced": {
      "weight": 0.15,
      "evidence": [
        "Reduced caffeine and theophylline metabolism",
        "May require dose adjustment"
      ],
      "drugs": [
        "caffeine",
        "theophylline",
        "clozapine",
        "amitriptyline"
      ]
    },
    "CYP2B6_reduced": {
      "weight": 0.2,
      "evidence": [
        "Reduced methadone and efavirenz metabolism",
        "May require dose adjustment"
      ],
      "drugs": [
        "methadone",
        "propofol"
      ]
    },
    "COMT_reduced": {
      "weight": 0.1,
      "evidence": [
        "Altered catecholamine metabolism",
        "May affect response to certain medications"
      ],
      "drugs": [
        "levodopa"
      ]
    },
    "SLC6A4_reduced": {
      "weight": 0.08,
      "evidence": [
        "Altered serotonin transporter function",
        "May affect SSRI response"
      ],
      "drugs": [
        "fluoxetine",
        "sertraline"
      ]
    }
  },
  "pathway_burden": {
    "weight": 0.25,
    "evidence": [
      "Multiple gene impairment in same pathway indicates higher risk",
      "Redundancy loss increases susceptibility to adverse events"
    ]
  },
  "clinical_guidelines": {
    "fda_boxed_warnings": [
      "CYP2D6 poor metabolizers: codeine contraindicated in children",
      "CYP2C19 poor metabolizers: clopidogrel may be less effective",
      "TPMT poor metabolizers: azathioprine/mercaptopurine contraindicated",
      "HLA-B*5701 positive: abacavir contraindicated",
      "HLA-B*5701 positive: carbamazepine contraindicated"
    ],
    "cpic_recommendations": [
      "CYP2D6 poor metabolizers: avoid codeine, consider morphine",
      "CYP2C19 poor metabolizers: consider prasugrel or ticagrelor",
      "CYP2C9 poor metabolizers: reduce warfarin dose by 25-50%",
      "SLCO1B1*5 carriers: reduce simvastatin dose or use alternative",
      "TPMT poor metabolizers: reduce thiopurine dose by 90%"
    ],
    "pharmgkb_levels": {
      "level_1a": "High evidence, clinical action recommended",
      "level_1b": "Moderate evidence, clinical action recommended",
      "level_2a": "Moderate evidence, clinical action suggested",
      "level_2b": "Low evidence, clinical action suggested",
      "level_3": "Low evidence, clinical action optional"
    }
  }
}